Eli Lilly and Company (NYSE:LLY) Releases FY 2025 Earnings Guidance

Eli Lilly and Company (NYSE:LLY - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 21.750-23.000 for the period, compared to the consensus estimate of 21.587. The company issued revenue guidance of $60.0 billion-$62.0 billion, compared to the consensus revenue estimate of $59.5 billion.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. UBS Group reduced their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $1,012.56.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $746.17 on Thursday. The company has a market capitalization of $707.17 billion, a P/E ratio of 60.71, a P/E/G ratio of 1.09 and a beta of 0.44. The company's 50-day simple moving average is $777.97 and its two-hundred day simple moving average is $800.20. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Institutional Investors Weigh In On Eli Lilly and Company

A hedge fund recently raised its stake in Eli Lilly and Company stock. Revolve Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,471 shares of the company's stock after purchasing an additional 40 shares during the period. Revolve Wealth Partners LLC's holdings in Eli Lilly and Company were worth $1,136,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.